Symposium:
187. The Challenge of Respiratory Viruses in Transplantation
Sunday, October 23, 2011: 7:30 AM-9:00 AM
Room: 205ABC

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the unique infection control challenges in caring for transplantation patients with possible or proven respiratory virus infection
  • cite recent advances in novel molecular methods of diagnosis
  • recognize newly identified viral pathogens causing viral respiratory illness
  • relate the impact of more sensitive diagnostic methods to infection control approaches
  • determine the role of novel therapies for treatment of viral respiratory infections

Target Audience: Infection Control Practitioners, Infectious Disease Practitioners, Pharmacists, Microbiologists, Lab Personnel, Clinicians, Academicians

Tracks: Pediatric ID, Adult ID

Moderators:  Kent A. Sepkowitz, MD, FIDSA, Memorial Sloan-Kettering Cancer Center and Kathryn Kirkland, MD, Dartmouth Hitchcock Medical Center

Presentations:

7:30 AM
Infection Control Issues
Kathryn Kirkland, MD

8:00 AM
New Diagnostic Approaches
Angela Caliendo, MD, PhD, FIDSA

8:30 AM
New and Emerging Therapies
Frederick Hayden, MD, FIDSA

CME Credits: Maximum of 1.5 hours of Category 1 credit possible

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-162-L01-P

Disclosures:

K. A. Sepkowitz, Department of Defense: Investigator, Research grant

K. Kirkland, None

K. Kirkland, None

A. Caliendo, Roche Diagnostics: Scientific Advisor, Consulting fee
Abbott Diagnostics: Scientific Advisor, Consulting fee
GenProbe: Scientific Advisor, Consulting fee
Quidel: Scientific Advisor, Consulting fee
Idaho Technologies: Scientific Advisor, Consulting fee
Biotrin: Consultant, Consulting fee
Roche Molecular: Investigator, Research support
Qiagen: Investigator, Research support

F. Hayden, Biocryst: Non-paid consultant, No compensation received
GSK: Non-paid consultant, No compensation received
Roche: Non-paid consultant, No compensation received
Nexbio: Non-paid consultant, No compensation received
Toyama: Non-paid consultant, No compensation received
Crucell: Non-paid consultant, No compensation received
Adamas: Non-paid consultant, No compensation received
AVIBio Pharma: Non-paid consultant, No compensation received
Intercell AG: Non-paid consultant, No compensation received
Aileron: Non-paid consultant, No compensation received
Alios: Non-paid consultant, No compensation received
Boehringer-Ingelheim: Non-paid consultant, No compensation received
Theraclone: Non-paid consultant, No compensation received
Vertex: Non-paid consultant, No compensation received
Kirin: Non-paid consultant, No compensation received
Abbott: Non-paid consultant, No compensation received
Respivert: Non-paid consultant, No compensation received
Vaxinnate: Non-paid consultant, No compensation received
3V Biosciences: Non-paid consultant, No compensation received
Zirus: Non-paid consultant, No compensation received
Farmak: Non-paid consultant, No compensation received
Synairgen: Non-paid consultant, No compensation received

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.